Pregnancy

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%

Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its…

3 months ago

Two Clinical Trials Identify a Better Way to Target Appropriate Antibiotics for Patients Hospitalized With Pneumonia or Urinary Tract Infection

Algorithm driven alerts help identify best antibiotic for patients with common infections in two 59-hospital trials, with implications to reduce…

3 months ago

GE HealthCare Introduces AI-Enhanced Voluson Signature 20 and 18 Ultrasound Systems to Advance Women’s Health Imaging

Integrated artificial intelligence (AI) and advanced tools improve image quality and exam speed to help providers make accurate diagnoses and…

3 months ago

Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence

Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a…

3 months ago

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health…

3 months ago

Radius Announces Presentation of Data on TYMLOS (abaloparatide) at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases

TYMLOS®demonstrated a lower incidence of hip fracture and non-vertebral fracture compared to teriparatide in women with osteoporosis 50 years and…

3 months ago

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone…

3 months ago

Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.

Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi, an operating company of Fresenius SE, with an intravenous and subcutaneous…

3 months ago

Digostics and AgaMatrix Partner to Introduce Oral Glucose Tolerance Home Testing for UK Expectant Mothers

Digostics and AgaMatrix Team Up to Improve Gestational Diabetes Screening for UK Women via the Introduction of Oral Glucose Tolerance…

3 months ago